How a Celiac Disease Autoantigen Slips Past the Body’s B-Cell Defences
A correction notice highlights a foundational study on the immune system’s failure to tolerate the enzyme transglutaminase 2, a key autoantigen in celiac disease. The original research investigated how B cells, which normally learn to ignore the body’s own proteins, can instead produce antibodies against this enzyme, triggering an autoimmune attack on the gut lining in genetically susceptible individuals.
Why it might matter to you:
This work delves into a fundamental mechanism of autoimmune pathology, directly relevant to understanding how immune tolerance breaks down. For a researcher focused on immune evasion and adjuvants, the principles of B-cell tolerance to self-antigens provide a critical counterpoint to vaccine design, where the goal is to break tolerance against foreign pathogens. Insights into these pathways could inform strategies for modulating immune responses in both autoimmune and transplantation contexts.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
